Navigation Links
Safe Options for Cardiac Lead Removal: Study Published in Heart Rhythm Journal
Date:5/12/2008

Spectranetics' Laser System Successfully Assists Removal of 975 Cardiac

Leads

COLORADO SPRINGS, Colo., May 12 /PRNewswire-FirstCall/ -- Spectranetics Corporation (Nasdaq: SPNC) today announced that a peer-reviewed study demonstrates Spectranetics' excimer laser sheath safely and effectively assists removal of pacing and defibrillator leads. The study, "Large, Single- catheter, Single-operator Experience with Transvenous Lead Extraction: Outcomes and Changing Indications," featured in the April issue of HeartRhythm, represents a seven year retrospective analysis of data from 498 lead extraction procedures involving 975 leads. The conclusion demonstrates safe extraction of leads successfully removed with laser assistance. HeartRhythm is the official journal of the Heart Rhythm Society and the Cardiac Electrophysiology Society.

As an escalating number of patients receive implanted cardiac devices, concerns surrounding lead management options are on the rise. Infection continues to be a primary cause for concern with leads, however, lead malfunction and patient lifespan are increasingly encouraging physicians to consider lead removal versus lead abandonment, the previous standard-of-care practice. Historically, safe, effective technologies designed to assist lead removal were limited but this is changing as new technologies enter the market and continue to receive clinical validation.

The Spectranetics Laser Sheath (SLS(R) II) use "cool" ultraviolet light to safely, effectively and efficiently ablate scar tissue that holds problematic leads in place. A circle of fibers that emit pulses of energy travel over the cardiac lead towards the tip to dissolve scar tissue that binds the lead to the body. Once the scar tissue is dissolved, the lead can be safely removed. Spectranetics' Lead Locking Device (LLD) technology can also be used to assist removal by creating secure traction during procedures that may or may not require laser assistance.

The retrospective study at Brigham and Women's Hospital in Boston was designed to examine indications, outcomes and complications associated with transvenous lead extraction. Dr. Laurence Epstein, Chief of Cardiac Arrhythmia Services at Brigham and Women's Hospital acted as the single-operator in the study handling all 498 lead extraction procedures throughout the seven year period. The study showed a success rate of over 97% with only two major complications, and no deaths. These two major complications out of 498 procedures resulted in a major complication rate of only 0.4%. The published article also highlights concerns surrounding existing formal recommendations for lead removal given the technologies available to assist the process. The article notes that "the rate of complications from abandoned leads reported in one study was as low as 5.5 percent, which still is higher than the complication rate from extraction."

"We were interested in reviewing our outcomes, at a high volume center with an experienced operator," said Dr. Epstein. "Historically the indications for lead extraction have been tempered by the risks, real and perceived, associated with the procedure. This study demonstrates that transvenous lead extraction can be performed safely and effectively in a wider population of patients." Dr. Epstein further describes his strategy, explaining, "Hopefully, this will reduce the number of patients subjected to open heart procedures and the risks and complications of abandoned leads. However, this is not an endorsement for the performance of extraction, more widely, in inexperienced hands. Excellent results are achieved through careful preparation, planning and experience."

About Spectranetics

Founded in 1984, Spectranetics manufactures and sells the only excimer laser approved in the United States, Europe and Japan for use in minimally invasive cardiovascular procedures. This technology treats complex cardiovascular conditions by photo-ablating multiple lesion types into tiny particles that are easily absorbed into the blood stream. The Company's disposable catheters use high-energy "cool" ultraviolet light to vaporize arterial blockages in the legs and heart, as well as scar tissue encapsulating pacing and defibrillation leads. For more information, visit http://www.spectranetics.com.

Stacey Holifield/Krystin Hayward

Schwartz Communications, Inc.,

(781) 684-0770

spectranetics@schwartz-pr.com


'/>"/>
SOURCE Spectranetics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ValueOptions(R) New Mexico Provides $10.3 Million for Community Behavioral Health Care Organizations
2. Keith Denner Extends Current Technologys Chairman and CEO Options
3. SNAPforSeniors Now Helps BenefitsCheckUp Users Locate Housing Options
4. Blue Cross Consumer-directed Health Plan - Options Blue - Members Not Sacrificing Health for the Sake of Saving Money
5. Guardian Expands Dental Benefit Options Helps Small Business Owners Lower Insurance Cost
6. NeurogesX to Present at Susquehanna Financial Groups 2nd Annual SIGnificant Options in Healthcare Conference
7. Novavax CEO to Present at Susquehannas Second SIGnificant Options in Healthcare Conference
8. Abaxis, Inc. to Present at the Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
9. Idenix Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference
10. Advanced Life Sciences to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference
11. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, located ... training and leads programs. , In February, 2017, Empower Brokerage introduced their new ... Partners is designed to teach how to maximize their sales efforts, as well ...
(Date:3/24/2017)... ... March 24, 2017 , ... “End Time GPS”: ... events will interrelate. “End Time GPS” is the creation of published author, Wesley ... while working on military munitions and space-vehicle projects. Now, at age ninety-one, he shares ...
(Date:3/24/2017)... ... ... Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story about a ... God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” is the ... writing, especially about truth and human behavior. , Published by Christian Faith Publishing, Patti ...
(Date:3/23/2017)... Texas (PRWEB) , ... March 23, 2017 , ... The ... 3rd location in the greater Houston Area. The new location is located at 2255 ... Luke’s Hospital in Springwoods Village. This newest location will provide patients living in the ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Center at 10 North Broadway Avenue, will be an educational and exciting program ... instruction in the management of chronic pain. , Oklahoma is in a healthcare ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets ... the U.S.: Consumer Strategies" report to their offering. ... Pain ... approach and treat their physical pain, emphasizing consumer survey analysis, ... pain sufferers and adults who have selected illnesses/conditions strongly associated ...
(Date:3/24/2017)... , March 24, 2017 ShangPharma, ... high-quality and cost-effective drug development and discovery ... and biotechnology industry, announced today the intent ... ShangPharma will be consolidating the Contract Research ... under Shanghai ChemPartner. These entities include ChemPartner ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with a ... Merck & Co., Inc., Biogen and Sanofi are involved in the development ... of which one is in Phase III stage, 15 are in Phase ...
Breaking Medicine Technology: